Alteraciones hematológicas producidas por el uso prolongado de la ceftriaxona.
Palabras clave:
Ceftriaxona, Hematología, Cefalosporinas, Utilización de medicamentos, Efectos adversos relacionados con medicamentos, AntibacterianosResumen
A lo largo del tiempo se ha aumentado el uso de antibióticos empíricamente, por ello se han podido evidenciar nuevos desenlaces secundarios al uso de estos. El objetivo del artículo es ampliar el conocimiento sobre la ceftriaxona, observando de manera directa los efectos no deseados que puedan presentarse. Para ello se realizó una revisión de literatura en la base de datos PubMed, con el uso de palabras claves como “efectos adversos relacionados con medicamentos”, “ceftriaxona”. Se evidenció efectos de importancia clínica, pero no es concluyente si el principal factor es el medicamento. Asimismo, la cantidad de casos reportados son muy pocos. Se concluye que la ceftriaxona, aunque pueda traer consigo efectos adversos graves, es un medicamento seguro, debido a que la incidencia de casos generados por este fármaco es muy baja. Además, se deben cumplir condiciones específicas como el uso prolongado y/o altas dosis de este.
Descargas
Citas
Alós. Resistencia bacteriana a los antibióticos: una crisis global. Enferm Infecc Microbiol Clin. 2015;33(10):692-9.
Muhammed OS, Nasir BB. Drug Use Evaluation of Ceftriaxone in Ras-Desta Memorial General Hospital, Ethiopia. Drug Healthc Patient Saf. 2020 10;12:161-168. DOI: 10.2147/DHPS.S260364
Lee H, Jung D, Yeom JS, Son JS, Jung SI, Kim YS, Kim CK, Chang HH, Kim SW, Ki HK, Moon CS, Chung DR, Peck KR, Song JH, Woo GJ. Evaluation of ceftriaxone utilization at multicenter study. Korean J Intern Med. 2009;24(4):374-80. DOI: 10.3904/kjim.2009.24.4.374
Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother. 2008;62 Suppl 1:i1-9. DOI: 10.1093/jac/dkn241
McEwen SA, Collignon PJ. Antimicrobial Resistance: a One Health Perspective. Microbiol Spectr. 2018;6(2). DOI: 10.1128/microbiolspec.ARBA-0009-2017
Roth N, Käsbohrer A, Mayrhofer S, Zitz U, Hofacre C, Domig KJ. The application of antibiotics in broiler production and the resulting antibiotic resistance in Escherichia coli: A global overview. Poult Sci. 2019;98(4):1791-804. DOI: 10.3382/ps/pey539
Donnelly PC, Sutich RM, Easton R, Adejumo OA, Lee TA, Logan LK. Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature. Paediatr Drugs. 2017;19(1):21-34. DOI: 10.1007/s40272-016-0197-x
Montané E, Santesmases J. Adverse drug reactions. Med Clin (Barc). 2020 13;154(5):178-84.,. DOI: 10.1016/j.medcli.2019.08.007.
Agunbiade A, Routsolias JC, Rizvanolli L, Bleifuss W, Sundaresan S, Moskoff J. The effects of ceftriaxone by intravenous push on adverse drug reactions in the emergency department. Am J Emerg Med. 2021; 43:245-48. DOI: 10.1016/j.ajem.2020.03.022
Sileshi A, Tenna A, Feyissa M, Shibeshi W. Evaluation of ceftriaxone utilization in medical and emergency wards of Tikur Anbessa specialized hospital: a prospective cross-sectional study. BMC Pharmacol Toxicol. 2016 18;17:7. DOI: 10.1186/s40360-016-0057-x.
Afriyie DK, Amponsah SK, Dogbey J, Agyekum K, Kesse S, Truter I, Meyer JC, Godman B. A pilot study evaluating the prescribing of ceftriaxone in hospitals in Ghana: findings and implications. Hosp Pract. 2017;45(4):143-49. DOI: 10.1080/21548331.2017.1348139.
Sileshi A, Tenna A, Feyissa M, Shibeshi W. Evaluation of ceftriaxone utilization in medical and emergency wards of Tikur Anbessa specialized hospital: a prospective cross-sectional study. BMC Pharmacol Toxicol. 2016 18;17:7. DOI: 10.1186/s40360-016-0057-x.
van der Meer JW, Gyssens IC. Quality of antimicrobial drug prescription in hospital. Clin Microbiol Infect. 2001;7 Suppl 6:12-5. DOI: 10.1046/j.1469-0691.2001.00079.x.
Pinto Pereira LM, Phillips M, Ramlal H, Teemul K, Prabhakar P. Third generation cephalosporin use in a tertiary hospital in Port of Spain, Trinidad: need for an antibiotic policy. BMC Infect Dis. 2004 15;4(1):59. DOI: 10.1186/1471-2334-4-59.
Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs. 2002;62(7):1041-89. DOI: 10.2165/00003495-200262070-00005
McGill F, Heyderman RS, Panagiotou S, Tunkel AR, Solomon T. Acute bacterial meningitis in adults. Lancet. 2016 17;388(10063):3036-47. DOI: 10.1016/S0140-6736(16)30654-7
Brouwer MC, van de Beek D. Epidemiology of community-acquired bacterial meningitis. Curr Opin Infect Dis. 2018;31(1):78-84. DOI: 10.1097/QCO.0000000000000417
Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Préziosi MP, Stuart JM. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. Lancet Infect Dis. 2017;17(8):867-72. DOI: 10.1016/S1473-3099(17)30301-8
Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23(3):467-92. DOI: 10.1128/CMR.00070-09.
Davis LE. Acute Bacterial Meningitis. Continuum (Minneap Minn). 2018;24(5, Neuroinfectious Disease):1264-283. DOI: 10.1212/CON.0000000000000660
Atkinson H, Wallis S, Coatesworth AP. Acute otitis media. Postgrad Med. 2015;127(4):386-90. DOI: 10.1080/00325481.2015.1028872.
Leung AKC, Wong AHC. Acute Otitis Media in Children. Recent Pat Inflamm Allergy Drug Discov. 2017;11(1):32-40. DOI: 10.2174/1874609810666170712145332
Ruohola A, Meurman O, Nikkari S, Skottman T, Salmi A, Waris M, Osterback R, Eerola E, Allander T, Niesters H, Heikkinen T, Ruuskanen O. Microbiology of acute otitis media in children with tympanostomy tubes: prevalences of bacteria and viruses. Clin Infect Dis. 2006;43(11):1417-22. DOI: 10.1086/509332. Epub 2006
Berhe YH, Amaha ND, Ghebrenegus AS. Evaluation of ceftriaxone use in the medical ward of Halibet National Referral and teaching hospital in 2017 in Asmara, Eritrea: a cross sectional retrospective study. BMC Infect Dis. 2019;19(1):465. DOI: 10.1186/s12879-019-4087-z
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. DOI: 10.1164/rccm.201908-1581ST
Sharma R, Sandrock CE, Meehan J, Theriault N. Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin. Clin Drug Investig. 2020;40(10):947-60. DOI: 10.1007/s40261-020-00953-z
Perry TR, Schentag JJ. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet. 2001;40(9):685-94. DOI: 10.2165/00003088-200140090-00004
Patel IH, Kaplan SA. Pharmacokinetic profile of ceftriaxone in man. Am J Med. 1984 19;77(4C):17-25.
Wang YK, Wu YE, Li X, Tian LY, Khan MW, Tang BH, Shi HY, Zheng Y, Hao GX, van den Anker J, You DP, Zhao W. Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis. Antimicrob Agents Chemother. 2020;64(11):e01412-20. DOI: 10.1128/AAC.01412-20
Brogden RN, Ward A. Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration. Drugs. 1988;35(6):604-45. DOI: 10.2165/00003495-198835060-0000
Blumer J. Pharmacokinetics of ceftriaxone. Hosp Pract (Off Ed). 1991;26 Suppl 5:7-13; discussion 52-4. DOI: 10.1080/21548331.1991.11707737
Scully BE, Fu KP, Neu HC. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. Am J Med. 1984;77(4C):112-6.
Zelenitsky SA, Beahm NP, Iacovides H, Ariano RE, Zhanel G. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. J Antimicrob Chemother. 2018 1;73(7):1888-894. DOI: 10.1093/jac/dky120.
Yuk JH, Nightingale CH, Quintiliani R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet. 1989;17(4):223-35. DOI: 10.2165/00003088-198917040-00002.
Montané E, Santesmases J. Adverse drug reactions. Med Clin (Barc). 2020 13;154(5):178-84.,. DOI: 10.1016/j.medcli.2019.08.007.
Agunbiade A, Routsolias JC, Rizvanolli L, Bleifuss W, Sundaresan S, Moskoff J. The effects of ceftriaxone by intravenous push on adverse drug reactions in the emergency department. Am J Emerg Med. 2021; 43:245-48. DOI: 10.1016/j.ajem.2020.03.022.
Arndt PA. Drug-induced immune hemolytic anemia: the last 30 years of changes. Immunohematology. 2014;30(2):44-54. DOI: 10.21307/immunohematology-2019-098
Hernández A, Roldán M, Herrera L, Martinez L. Anemia hemolítica asociada a fármacos antimicrobianos. Enfermedades Infecciosas y Microbiología. 2018; 38:81-85. DOI: 10.47373/rfcs.2020.v22.1510
Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24(4-5):143-50. DOI: 10.1016/j.blre.2010.06.004. Epub 2010.
Kumar S, Bansal R, Bansal P, Dhamija RK, Neurology D. Ceftriaxone-Induced Hemolytic Anemia: A Rare Case Report. Perm J. 2020; 24:19.088. DOI: 10.7812/TPP/19.088.
Mulkens CE, van Lochem EG, Folman CC, van der Spek E, van Leeuwen HJ. Hemolyse en multiorgaanfalen door ceftriaxon [Ceftriaxone-induced immune haemolytic anaemia and multi-organ failure]. Ned Tijdschr Geneeskd. 2015;159:A8054. DOI: 10.7759/cureus.8660
Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A; British Society for Haematology Guidelines. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177(2):208-20. DOI: 10.1111/bjh.14654.
Leicht HB, Weinig E, Mayer B, Viebahn J, Geier A, Rau M. Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature. BMC Pharmacol Toxicol. 2018;19(1):67. DOI: 10.1186/s40360-018-0257-7.
Renard D, Rosselet A. Drug-induced hemolytic anemia: Pharmacological aspects. Transfus Clin Biol. 2017;24(3):110-14. DOI: 10.1016/j.tracli.2017.05.013.
Curtis BR. Drug-induced immune neutropenia/agranulocytosis. Immunohematology. 2014;30(2):95-101. DOI: 10.21307/immunohematology-2019-103
Couto L, Goulart A, Valadão I, Garça M, Santos MB, Cota P, Teixeira C. Ceftriaxone-induced Agranulocytosis. Eur J Case Rep Intern Med. 2021;8(1):002215. DOI: 10.12890/2021_002215.
Andrès E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008;15(1):15-21. DOI: 10.1097/MOH.0b013e3282f15fb9
Neftel KA, Hauser SP, Müller MR. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infect Dis. 1985; 152(1):90-8. DOI: 10.1093/infdis/152.1.90.
Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146(9):657-65. DOI: 10.7326/0003-4819-146-9-200705010-00009
Bennett S, Hoffman N, Monga M. Ephedrine- and guaifenesin-induced nephrolithiasis. J Altern Complement Med. 2004;10(6):967-69. DOI: 10.1089/acm.2004.10.967.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Salutem Scientia Spiritus
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
